MDL 201
Alternative Names: MDL-201Latest Information Update: 29 Sep 2020
At a glance
- Originator Modalis Therapeutics
- Class Gene therapies
- Mechanism of Action Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Musculoskeletal disorders
Most Recent Events
- 04 Sep 2020 Modalis Therapeutics plans to submit IND application for Musculoskeletal disorders in 2021
- 28 Aug 2020 Preclinical trials in Musculoskeletal disorders in Japan (Parenteral) before August 2020
- 01 Apr 2020 Modalis Therapeutics in-licenses CRISPR gene editing technology from Editas Medicine